Floatz logo

Anti-Her2 Antibody-Drug Conjugate A166

HER2 Positive Breast Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.antibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

175 Active assets in the HER2 Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Trastuzumab
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB
Cyclophosphamide
National University Hospital, Singapore
Phase 3BB
Capecitabine
MedSIR
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Her2 Antibody-Drug Conjugate A166 is also rated in:

breast cancerActive
B
Indicative · Phase 2
56 / 100
View asset →
gastric adenocarcinomaDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →